The Europe subcutaneous immunoglobulin (SCIG) sector is experiencing accelerated growth due to rising awareness of primary immunodeficiency diseases (PIDs), increasing preference for home-based therapy, and advancements in biologics. Valued at USD 2.5 billion in 2024, the sector is projected to grow at a CAGR of 9.0% from 2025 to 2034, reaching USD 5.9 billion by 2034....